766-40-5

Basic information

• Product Name: 3,4-dichloro-5-hydroxyfuran-2(5H)-one
• Synonyms: 3,4-dichloro-5-hydroxyfuran-2(5H)-one;3,4-(dichloro)-5-hydroxy-2(5H)-furanone;MUCOCHLORICACIDLACTONE;3,4-(DICHLORO)-5-HYDROXY-2-FURANONE;3,4-Dichloro-5-Hydroxy-5H-Furan-2-one;3,4-dichloro-5-hydroxy-3H-furan-2-one;3,4-dichloro-2-hydroxy-2H-furan-5-one
• CAS NO: 766-40-5
• Molecular Formula: C₄H₂Cl₂O₃
• Molecular Weight: 168.96288
• EINECS: 212-166-3
• Mol File: 766-40-5.mol
• Article Data: 6

Chemical Properties

• Melting Point: 127 °C(Solv: water (7732-18-5))
• Boiling Point: 367.2 °C at 760 mmHg
• Flash Point: 100 °C
• Appearance: /
• Density: 1.79 g/cm³
• Vapor Pressure: 6.97E-07mmHg at 25°C
• Refractive Index: 1.572
• Storage Temp.: 2-8°C
• PKA: 8.29±0.60(Predicted)
• CAS DataBase Reference: 3,4-dichloro-5-hydroxyfuran-2(5H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-dichloro-5-hydroxyfuran-2(5H)-one(766-40-5)
• EPA Substance Registry System: 3,4-dichloro-5-hydroxyfuran-2(5H)-one(766-40-5)

Safety Data

• Hazardous Substances Data: 766-40-5(Hazardous Substances Data)

Usage

Synthesis Reference(s)

The Journal of Organic Chemistry, 29, p. 1371, 1964 DOI: 10.1021/jo01029a024

InChI:InChI=1/C4H2Cl2O3/c5-1-2(6)4(8)9-3(1)7/h3,7H

Upstream product

• 117869-21-3 C₁₀H₅BrCl₂O₂S 
• 15341-59-0 3,4-dichlorofuran 
• 7697-37-2 nitric acid 
• 110-65-6 1,4-dihydroxybut-2-yne 
• 2892-56-0 cis-α-H-Tetrachlorcrotonylchlorid 
• 40636-99-5 4-chloro-5-hydroxy-<5H>-furan-2-one 
• 3200-96-2 2,3,4,4-tetrachloro-cyclobut-2-en-1-one 
• 88-14-2 2-furanoic acid 
• 98-01-1 furfural 

Downstream Products

• 805233-60-7 (3,4-dichloro-5-oxo-2,5-dihydro-furan-2-yl)phenylformamide 
• 247097-52-5 (3,4-dichloro-5-oxo-2,5-dihydro-furan-2-yl)methylformamide 
• 749849-35-2 4-chloro-6-methyl-2-oxa-6-azabicyclo[3.1.0]hex-4-en-3-one 
• 934239-58-4 2,3-dichloro-4-phenylimino-but-2-enoic acid 
• 84956-71-8 2-tert-butyl-4,5-dichloro-2H-pyridazin-3-one 
• 1610692-98-2 3-chloro-4-(3,5-di-tert-butyl-4-hydroxyphenylsulfanyl)-5-hydroxyfuran-2(5H)-one 
• 1610692-99-3 4-benzylsulfanyl-3-chloro-5-hydroxyfuran-2(5H)-one 
• 117869-21-3 C₁₀H₅BrCl₂O₂S 
• 31350-39-7 dibromomethyl-p-tolyl sulfone 
• 41931-11-7 4,5-dichloro-2-(3-chlorophenyl)-2H-pyridazin-3-one 
• 933-76-6 4,5-dichloro-2-methyl-3(2H)-pyridazinone 

Relevant articles and documents

Aquaculture used for preventing fouling organisms are attached to and of the ketone derivative and its preparation method

The invention belongs to the technical field of medicine and provides furanone derivatives as shown in a formula (I) described in the specification or pharmaceutically acceptable salts thereof. The invention further provides a preparation method and application of the furanone derivatives or pharmaceutically acceptable salts thereof which are used as main active ingredients for inhibiting diseases and insect pests of marine products and biofouling.

Preparation and biodistribution of [18F]FP2OP as myocardial perfusion imaging agent for positron emission tomography

Myocardial extractions of pyridaben, a mitochondrial complex I (MC-I) inhibitor, is well correlated with blood flow. Based on the synthesis and characterization of pyridaben analogue 2-tert-butyl-5-[2-(2-[18F]fluroethoxy)ethoxy]benzyloxy]-4-chloro-2H-pyridazin-3-one ([18F]FP2OP), this study assessed its potential to be developed as myocardial perfusion imaging (MPI) agent. Methods: The tosylate labeling precursor 2-(2-(4-(tert-butyl-5-chloro-6-oxo-1,6-dihydro-pyridazin-4-yloxymethyl)benzyloxy)ethoxy)ethyl ester (OTs-P2OP) and the nonradioactive 2-tert-butyl-5-[2-(2-[19F]fluroethoxy)ethoxy]benzyloxy]-4-chloro-2H-pyridazin-3-one ([19F]FP2OP) were synthesized and characterized by IR, 1H NMR, 13C NMR and MS analysis. By substituting tosyl of precursor OTs-P2OP with 18F, the radiolabeled complex [18F]FP2OP was prepared and further evaluated for its in vitro physicochemical properties, in vivo biodistribution, the metabolic stability in mice, ex vivo autoradiography and cardiac PET/CT imaging. Results: Starting with [18F]F- Kryptofix 2.2.2./K2CO3 solution, the total reaction time for [18F]FP2OP was about 100 min, with final high-performance liquid chromatography purification included. Typical decay-corrected radiochemical yield stayed at 41 ± 5.3%, the radiochemical purity, 98% or more. Biodistribution in mice showed that the heart uptake of [18F]FP2OP was 41.90 ± 4.52%ID/g at 2 min post-injection time, when the ratio of heart/liver, heart/lung and heart/blood reached 6.83, 9.49 and 35.74, respectively. Lipophilic molecule was further produced by metabolized [18F]FP2OP in blood and urine at 30 min. Ex vivo autoradiography demonstrates that [18F]FP2OP may have high affinity with MC-I and that can be blocked by [19F]FP2OP or rotenone (a known MC-I inhibitor). Cardiac PET images were obtained in a Chinese mini-swine at 5, 15, 30 and 60 min post-injection time with high quality. Conclusion: [18F]FP2OP was synthesized with high radiochemical yield. The promising biological properties of [18F]FP2OP suggest high potential as MPI agent for positron emission tomography in the future.

Synthesis of chlorinated 5-hydroxy 4-methyl-2(5H)-furanones and mucochloric acid

An improved procedure for the synthesis of chlorinated 5-hydroxy-4-methyl-2(5H)-furanones is described. By this method also carbon-labelled (13C and 14C at C-3) hydroxyfuranones, including mucochloric acid, can be prepared. Each step of the method was examined in an effort to optimize both the yield and the purity of the compounds.